Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-34412 Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW 0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma III Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor vorinostat; KW-0761 (mogamulizumab)
NCI-2014-00118 A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients With Chronic Lymphocytic Leukemia (CLL) III Chemotherapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor fludarabine; rituximab; cyclophosphamide; ibrutinib
715 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity (RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo-BM) for Patients With Hematologic Malignancies (BMT CTN #1101) III Immunotherapy Not Applicable
UPCC 13413 Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas II Immunotherapy CART 19
710 Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals II Chemotherapy, Radiotherapy fludarabine; busulfan; melphalan; cyclophosphamide
CD-ON-MEDI-551-1088 A Phase 2 Randomized Open-label Study of an Investigational Drug in Adults With Relapsed or Refractory DLBCL II Chemotherapy, Hormonal Therapy, Immunotherapy (Monoclonal Antibody) carboplatin; cisplatin; etoposide; ifosfamide; rituximab; cytarabine; dexamethasone; MEDI-551
UPCC-03411 A Phase I/IIa, Dose-Ranging Safety and Efficacy Study of Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma I / II Immunotherapy resiquimod
UPCC-11411 Maintenance Lenalidomide in Lymphoma I / II Immunomodulatory Agent lenalidomide
UPCC-17413 A Phase I/II Study Of Brentuximab Vedotin In Combination With Multi-Agent Chemotherapy As Front-Line Treatment In Patients With CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, And Grey Zone Lymphomas I / II Immunotherapy (Monoclonal Antibody), Antibody-Drug Conjugate brentuximab vedotin
CO-338-010 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor I / II PARP Inhibitor rucaparib
UPCC 12414 A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA I Antibody-Drug Conjugate GSK2857916
UPCC 25414 A Phase Ib, Open-Label Study Evaluating The Safety And Pharmacokinetics Of GDC-0199 (ABT-199) In Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine And Prednisone (Chope) In Patients With B-Cell Non-Hodgkins Lymphoma (NHL) and DLBCL I Biological Therapy, Chemotherapy, Hormonal Therapy, Immunotherapy (Monoclonal Antibody) vincristine; rituximab; prednisone; cyclophosphamide; doxorubicin; obinutuzumab; GDC-0199 (ABT-199 / RG7601)
UPCC 01614 A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor altiratinib
UPCC-03714 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Hematological Malignancies I Signal Transduction Inhibitor CB-839
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
UPCC-11111 A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy III Supportive Care GW-1000-02 (Sativex)
UPCC-14111 A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain III Other GW-1000-02 (Sativex)
UPCC-04712 A Phase II Study to Assess the Efficacy of Maraviroc, a CCR5-Antagonist in Prophylaxis of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Reduced-Intensity Allogeneic Stem-Cell Transplantation From Unrelated Donors II Antiviral Therapy Maraviroc
UPCC 01914 Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors Not Specified Pain Management Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood Test Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Phase 1: Solid Tumor Trials trials

Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug

Sorry, your search did not return any Proton Therapy Trials trials

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.